Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
A febrile disease occurring as a delayed sequela of infections with STREPTOCOCCUS PYOGENES. It is characterized by multiple focal inflammatory lesions of the connective tissue structures, such as the heart, blood vessels, and joints (POLYARTHRITIS) and brain, and by the presence of ASCHOFF BODIES in the myocardium and skin.
Cardiac manifestation of systemic rheumatological conditions, such as RHEUMATIC FEVER. Rheumatic heart disease can involve any part the heart, most often the HEART VALVES and the ENDOCARDIUM.
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
A chronic inflammatory condition affecting the axial joints, such as the SACROILIAC JOINT and other intervertebral or costovertebral joints. It occurs predominantly in young males and is characterized by pain and stiffness of joints (ANKYLOSIS) with inflammation at tendon insertions.
A subspecialty of internal medicine concerned with the study of inflammatory or degenerative processes and metabolic derangement of connective tissue structures which pertain to a variety of musculoskeletal disorders, such as arthritis.
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
Arthritis of children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent.
Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.
Arthritis is a general term used to describe inflammation in the joints, often resulting in pain, stiffness, and reduced mobility, which can be caused by various conditions such as osteoarthritis, rheumatoid arthritis, gout, or lupus.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
A small round or oval, mostly subcutaneous nodule made up chiefly of a mass of Aschoff bodies and seen in cases of rheumatic fever. It is differentiated from the RHEUMATOID NODULE which appears in rheumatoid arthritis, most frequently over bony prominences. (From Dorland, 27th ed)
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
Antibodies found in adult RHEUMATOID ARTHRITIS patients that are directed against GAMMA-CHAIN IMMUNOGLOBULINS.
Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.
A type of inflammatory arthritis associated with PSORIASIS, often involving the axial joints and the peripheral terminal interphalangeal joints. It is characterized by the presence of HLA-B27-associated SPONDYLARTHROPATHY, and the absence of rheumatoid factor.
Relocating a patient to a CLIMATE more suitable for health or for management of a health condition.
Inflammation of the SPINE. This includes both arthritic and non-arthritic conditions.
An aseptic, inflammatory arthritis developing secondary to a primary extra-articular infection, most typically of the GASTROINTESTINAL TRACT or UROGENITAL SYSTEM. The initiating trigger pathogens are usually SHIGELLA; SALMONELLA; YERSINIA; CAMPYLOBACTER; or CHLAMYDIA TRACHOMATIS. Reactive arthritis is strongly associated with HLA-B27 ANTIGEN.
Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.
A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence.
Hereditary metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi.
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
The noninvasive microscopic examination of the microcirculation, commonly done in the nailbed or conjunctiva. In addition to the capillaries themselves, observations can be made of passing blood cells or intravenously injected substances. This is not the same as endoscopic examination of blood vessels (ANGIOSCOPY).
The clear, viscous fluid secreted by the SYNOVIAL MEMBRANE. It contains mucin, albumin, fat, and mineral salts and serves to lubricate joints.
I'm sorry for any confusion, but "Portugal" is not a medical term and does not have a medical definition. It is a country located in southwestern Europe, known for its rich history, culture, and contributions to various fields including medicine. If you have any questions related to medical topics or definitions, I would be happy to help!
Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.
A common nonarticular rheumatic syndrome characterized by myalgia and multiple points of focal muscle tenderness to palpation (trigger points). Muscle pain is typically aggravated by inactivity or exposure to cold. This condition is often associated with general symptoms, such as sleep disturbances, fatigue, stiffness, HEADACHES, and occasionally DEPRESSION. There is significant overlap between fibromyalgia and the chronic fatigue syndrome (FATIGUE SYNDROME, CHRONIC). Fibromyalgia may arise as a primary or secondary disease process. It is most frequent in females aged 20 to 50 years. (From Adams et al., Principles of Neurology, 6th ed, p1494-95)
Organizations involved in all aspects of health planning activities.
Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body.
A syndrome in the elderly characterized by proximal joint and muscle pain, high erythrocyte sedimentation rate, and a self-limiting course. Pain is usually accompanied by evidence of an inflammatory reaction. Women are affected twice as commonly as men and Caucasians more frequently than other groups. The condition is frequently associated with GIANT CELL ARTERITIS and some theories pose the possibility that the two diseases arise from a single etiology or even that they are the same entity.
A specific HLA-B surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-B*27 allele family.
Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as CHOREATIC DISORDERS. Chorea is also a frequent manifestation of BASAL GANGLIA DISEASES.
Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9)
Inflammation of a muscle or muscle tissue.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.

MHC class II gene associations with autoantibodies to U1A and SmD1 proteins. (1/856)

Autoantibodies against U small nuclear ribonucleoproteins (snRNP) are frequently present in the serum of patients with systemic rheumatic diseases, and have been reported to be associated with HLA-DR and -DQ genes. To better define the role of HLA genes in the production of such antibodies, we studied immunogenetic associations with autoantibodies reacting with U1 RNP, U1A and SmD1 proteins, and synthetic peptides containing immunodominant linear epitopes of these proteins. Only two out of the 15 overlapping peptides of U1A (i.e. peptides 35-58 and 257-282) and three of 11 peptides of SmD1 (i.e. peptides 1-20, 44-67 and 97-119) were significantly recognized by patients' sera selected on the basis of their antibody positivity with RNP in immunodiffusion. The distribution of DRB1, DQB1 and DPB1 alleles among the anti-RNP antibody-positive patients (n = 28) and healthy control subjects was similar. Antibodies against U1A (tested in Western immunoblotting with HeLa cell extracts) were positively associated to DRB1*06 allele; antibodies reacting with SmD1 peptide 44-67 were negatively associated to DRB1*02 and DQB1*0602 alleles. No association was found between DPB1 alleles and antibodies reacting with U1A and SmD1 antigens. This first study reporting an association between autoantibodies reacting with U1A and SmD1 proteins (and peptides of these proteins), and immunogenetic markers suggest that the production of antibody subsets directed against different components (or regions of these proteins) bound to the same snRNP particle is associated with distinct MHC class II alleles.  (+info)

Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection. (2/856)

OBJECTIVES: To investigate the association of cryoglobulinaemia and rheumatic manifestations in Korean patients with hepatitis C virus (HCV) infection. METHODS: Forty nine Korean patients with HCV infection were recruited. The prevalence, concentration, and type of cryoglobulin (by immunofixation), rheumatoid factor (RF), antinuclear antibody (ANA), and various rheumatological symptoms were investigated and HCV genotype was determined by polymerase chain reaction with genotype specific primer. RESULTS: The prevalence of cryoglobulin was 59% in Korean HCV patients and the concentration of cryoglobulin was 9.8 (7.9) g/l (mean (SD)). The type of cryoglobulinaemia was identified in 23 (80%) of 29 HCV patients with cryoglobulinaemia and they were all type III. There were no differences in age, sex, history of operation and transfusion, proportion of liver cirrhosis between the patients with cryoglobulinaemia and those without cryoglobulinaemia. The frequencies of RF and ANA were 14% and 3.4% respectively in HCV patients with cryoglobulinaemia. There was no difference in HCV genotype between the patients with cryoglobulinaemia and those without cryoglobulinaemia. Clinical features of HCV patients were as follows: arthralgia/arthritis (35%), cutaneous manifestation (37%), Raynaud's phenomenon (8%), paresthesia (44%), dry eyes (22%), dry mouth (10%), oral ulcer (33%), and abdominal pain (14%). However, these rheumatological symptoms did not differ between the two groups. CONCLUSION: Although the rheumatological symptoms were not different between HCV patients with and without cryoglobulinaemia, HCV patients showed various rheumatological manifestations. These result suggests that HCV infection could be included as one of the causes in patients with unexplained rheumatological symptoms.  (+info)

Nuclear factor-kappa B activity in T cells from patients with rheumatic diseases: a preliminary report. (3/856)

OBJECTIVE: The NF-kappa B/Rel family of transcription factors regulates the expression of many genes involved in the immune or inflammatory response at the transcriptional level. The aim of this study was to determine whether distinctive patterns of NF-kappa B activation are seen in different forms of joint disease. METHODS: The DNA binding activity of these nucleoproteins was examined in purified synovial and peripheral T cells from patients with various chronic rheumatic diseases (12: four with rheumatoid arthritis; five with spondyloarthropathies; and three with osteoarthritis). RESULTS: Electrophoretic mobility shift assays disclosed two specific complexes bound to a NF-kappa B specific 32P-labelled oligonucleotide in nucleoproteins extracted from purified T cells isolated from synovial fluid and peripheral blood of patients with rheumatoid arthritis. The complexes consisted of p50/p50 homodimers and p50/p65 heterodimers. Increased NF-kappa B binding to DNA in synovial T cells was observed relative to peripheral T cells. In non-rheumatoid arthritis, binding of NF-kappa B in synovial T cells was exclusively mediated by p50/p50 homodimers. CONCLUSION: Overall, the results suggest that NF-kappa B may play a central part in the activation of infiltrating T cells in chronic rheumatoid arthritis. The activation of this nuclear factor is qualitatively different in rheumatoid synovial T cells to that in other forms of non-rheumatoid arthritis (for example, osteoarthritis, spondyloarthropathies).  (+info)

Inhibition of protein denaturation by fatty acids, bile salts and other natural substances: a new hypothesis for the mechanism of action of fish oil in rheumatic diseases. (4/856)

Natural hydrophobic substances like bile salts (cholate, deoxycholate, chenodeoxycholate, lithocholate and their conjugates with glycine and taurine), fatty acids (caprylic, capric, lauric, myristic, palmitic, stearic, oleic, linoleic, arachidonic, eicosapentaenoic and docosahexaenoic acid) were much more active (EC50 approximately 10(-4)-10(-5) M) than selected amino acids (EC50 > 10(-2) M) and inorganic salts (EC50 approximately 10(-1) M) in inhibiting heat-induced denaturation of human serum albumin in vitro. Fish oil, rich in n-3-polyunsaturated acids such as eicosapentaenoic acid and docosahexaenoic acid, administered p.o. (1 ml/kg) in the rat, protected ex vivo (after 2 hr) serum against heat-induced denaturation more than bendazac, a known antidenaturant drug. Thus, we speculated that the antidenaturant activity of fish oil may be partly (in addition to the known effect on endogenous eicosanoid composition) responsible for its beneficial effects in rheumatoid arthritis and other rheumatic conditions. In this connection, it is of note that the in vitro antidenaturant activity of fish oil fatty acids was higher than that of known antidenaturant drugs such as bendazac and bindarit and nonsteroidal anti-inflammatory drugs like phenylbutazone and indomethacin which could exert beneficial effects in chronic inflammatory conditions by stabilizing endogenous proteins.  (+info)

Rheumatic disease and the Australian aborigine. (5/856)

OBJECTIVE: To document the frequency and disease phenotype of various rheumatic diseases in the Australian Aborigine. METHODS: A comprehensive review was performed of the archaeological, ethnohistorical, and contemporary literature relating to rheumatic diseases in these indigenous people. RESULTS: No evidence was found to suggest that rheumatoid arthritis (RA), ankylosing spondylitis (AS), or gout occurred in Aborigines before or during the early stages of white settlement of Australia. Part of the explanation for the absence of these disorders in this indigenous group may relate to the scarcity of predisposing genetic elements, for example, shared rheumatoid epitope for RA, B27 antigen for AS. In contrast, osteoarthritis appeared to be common particularly involving the temporomandibular joint, right elbow and knees and, most probably, was related to excessive joint loading in their hunter gatherer lifestyle. Since white settlement, high frequency rates for rheumatic fever, systemic lupus erythematosus, and pyogenic arthritis have been observed and there are now scanty reports of the emergence of RA and gout in these original Australians. CONCLUSION: The occurrence and phenotype of various rheumatic disorders in Australian Aborigines is distinctive but with recent changes in diet, lifestyle, and continuing genetic admixture may be undergoing change. An examination of rheumatic diseases in Australian Aborigines and its changing phenotype may lead to a greater understanding of the aetiopathogenesis of these disorders.  (+info)

Impact of arthritis and other rheumatic conditions on the health-care system--United States, 1997. (6/856)

Arthritis and other rheumatic conditions are the leading cause of disability in the United States, affecting approximately 43 million persons and costing $65 billion in 1992. By 2020, these numbers will increase as the population ages. This report examines several measures of the impact of arthritis on the U.S. health-care system; the findings indicate that arthritis and other rheumatic conditions have a large impact on hospitalizations, ambulatory-care visits, and home health care, with women accounting for most of this impact and all persons aged <65 years accounting for a substantial portion.  (+info)

Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece. (7/856)

In Greece a 15-day treatment of rheumatic disease with diclofenac costs 56% more than treatment with nimesulide. This is due to the lower incidence of gastrointestinal adverse events with nimesulide, and the absence of serious gastrointestinal complications leading to hospitalization, which more than offset the higher acquisition cost of nimesulide. The average saving by using nimesulide instead of diclofenac is about US$21 per patient for a 15-day treatment period.  (+info)

HLA-DRB1 genes in 5 rheumatic disease multi-case families. (8/856)

OBJECTIVE: To detect HLA-DRB1 (DR1-10) alleles in 5 families with multi-case rheumatic diseases, and to study the possible influence of DRB1 genes in the pathogenesis of rheumatic diseases. METHODS: Sequence-Specific Primer PCR (PCR-SSP) method was used to examine HLA-DRB1 alleles. Totally 36 members of 5 families and 166 healthy people were involved in this study. The results were assessed by Chi-square test. RESULTS: The HLA-DRB1 allele frequency in the patients and their relatives was similar. No significant difference was found. But DR4 allele frequency in the patients (90.9%) and their relatives (68%) was much higher than that in normal controls (16.8%) and the difference was statistically significant (P < 0.0001). In family 4, two RA patients have different DRB1 alleles, while in family 5, two patients have the same DRB1 alleles, one developed SLE and the other developed RA. CONCLUSIONS: DR4 is closely related to rheumatoid arthritis. The nelatives of RA patients may be at greater risk to develop RA than individuals without family history. Some patients had the same DRB1 allele but developed different rheumatic diseases. This suggested that there might be some common pathways in genetic predisposing of rheumatic diseases. On the other hand, only a few patients with the same DRB1 allele developed rheumatic diseases during their life, so other factors besides DRB1 gene might also be involved in the pathogenesis of rheumatic diseases.  (+info)

Rheumatic diseases are a group of disorders that cause pain, stiffness, and swelling in the joints, muscles, tendons, ligaments, or bones. They include conditions such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus (SLE), gout, ankylosing spondylitis, psoriatic arthritis, and many others. These diseases can also affect other body systems including the skin, eyes, lungs, heart, kidneys, and nervous system. Rheumatic diseases are often chronic and may be progressive, meaning they can worsen over time. They can cause significant pain, disability, and reduced quality of life if not properly diagnosed and managed. The exact causes of rheumatic diseases are not fully understood, but genetics, environmental factors, and immune system dysfunction are believed to play a role in their development.

Rheumatic fever is a systemic inflammatory disease that may occur following an untreated Group A streptococcal infection, such as strep throat. It primarily affects children between the ages of 5 and 15, but it can occur at any age. The condition is characterized by inflammation in various parts of the body, including the heart (carditis), joints (arthritis), skin (erythema marginatum, subcutaneous nodules), and brain (Sydenham's chorea).

The onset of rheumatic fever usually occurs 2-4 weeks after a streptococcal infection. The exact cause of the immune system's overreaction leading to rheumatic fever is not fully understood, but it involves molecular mimicry between streptococcal antigens and host tissues.

The Jones Criteria are used to diagnose rheumatic fever, which include:

1. Evidence of a preceding streptococcal infection (e.g., positive throat culture or rapid strep test, elevated or rising anti-streptolysin O titer)
2. Carditis (heart inflammation), including new murmurs or changes in existing murmurs, electrocardiogram abnormalities, or evidence of heart failure
3. Polyarthritis (inflammation of multiple joints) – typically large joints like the knees and ankles, migratory, and may be associated with warmth, swelling, and pain
4. Erythema marginatum (a skin rash characterized by pink or red, irregularly shaped macules or rings that blanch in the center and spread outward)
5. Subcutaneous nodules (firm, round, mobile lumps under the skin, usually over bony prominences)
6. Sydenham's chorea (involuntary, rapid, irregular movements, often affecting the face, hands, and feet)

Treatment of rheumatic fever typically involves antibiotics to eliminate any residual streptococcal infection, anti-inflammatory medications like corticosteroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to manage symptoms and prevent long-term heart complications, and secondary prophylaxis with regular antibiotic administration to prevent recurrent streptococcal infections.

Rheumatic Heart Disease (RHD) is defined as a chronic heart condition caused by damage to the heart valves due to untreated or inadequately treated streptococcal throat infection (strep throat). The immune system's response to this infection can mistakenly attack and damage the heart tissue, leading to inflammation and scarring of the heart valves. This damage can result in narrowing, leakage, or abnormal functioning of the heart valves, which can further lead to complications such as heart failure, stroke, or infective endocarditis.

RHD is a preventable and treatable condition if detected early and managed effectively. It primarily affects children and young adults in developing countries where access to healthcare and antibiotics for strep throat infections may be limited. Long-term management of RHD typically involves medications, regular monitoring, and sometimes surgical intervention to repair or replace damaged heart valves.

Rheumatoid arthritis (RA) is a systemic autoimmune disease that primarily affects the joints. It is characterized by persistent inflammation, synovial hyperplasia, and subsequent damage to the articular cartilage and bone. The immune system mistakenly attacks the body's own tissues, specifically targeting the synovial membrane lining the joint capsule. This results in swelling, pain, warmth, and stiffness in affected joints, often most severely in the hands and feet.

RA can also have extra-articular manifestations, affecting other organs such as the lungs, heart, skin, eyes, and blood vessels. The exact cause of RA remains unknown, but it is believed to involve a complex interplay between genetic susceptibility and environmental triggers. Early diagnosis and treatment are crucial in managing rheumatoid arthritis to prevent joint damage, disability, and systemic complications.

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that can affect almost any organ or system in the body. In SLE, the immune system produces an exaggerated response, leading to the production of autoantibodies that attack the body's own cells and tissues, causing inflammation and damage. The symptoms and severity of SLE can vary widely from person to person, but common features include fatigue, joint pain, skin rashes (particularly a "butterfly" rash across the nose and cheeks), fever, hair loss, and sensitivity to sunlight.

Systemic lupus erythematosus can also affect the kidneys, heart, lungs, brain, blood vessels, and other organs, leading to a wide range of symptoms such as kidney dysfunction, chest pain, shortness of breath, seizures, and anemia. The exact cause of SLE is not fully understood, but it is believed to involve a combination of genetic, environmental, and hormonal factors. Treatment typically involves medications to suppress the immune system and manage symptoms, and may require long-term management by a team of healthcare professionals.

Ankylosing spondylitis is a type of inflammatory arthritis that primarily affects the spine, although other joints can also be involved. It causes swelling in the spinal joints (vertebrae) that can lead to stiffness and pain. Over time, some of these joints may grow together, causing new bone formation and resulting in a rigid spine. This fusion of the spine is called ankylosis.

The condition typically begins in the sacroiliac joints, where the spine connects to the pelvis. From there, it can spread up the spine and potentially involve other areas of the body such as the eyes, heart, lungs, and gastrointestinal system.

Ankylosing spondylitis has a strong genetic link, with most people carrying the HLA-B27 gene. However, not everyone with this gene will develop the condition. It primarily affects males more often than females and tends to start in early adulthood.

Treatment usually involves a combination of medication, physical therapy, and exercise to help manage pain, maintain mobility, and prevent deformity. In severe cases, surgery may be considered.

Rheumatology is a subspecialty of internal medicine that deals with the diagnosis and management of more than 200 diseases affecting the joints, muscles, and bones. These diseases are often complex, chronic, and systemic, meaning they can affect the whole body. Some common rheumatic diseases include rheumatoid arthritis, osteoarthritis, lupus, gout, osteoporosis, and various forms of vasculitis and connective tissue disorders.

Rheumatologists are medical doctors who have completed additional training in this field, becoming experts in the non-surgical treatment of musculoskeletal diseases. They use a combination of physical examination, patient history, laboratory testing, and imaging to diagnose and manage these conditions. Treatment may involve medications, lifestyle changes, physical therapy, or a combination of these approaches.

Connective tissue diseases (CTDs) are a group of disorders that involve the abnormal production and accumulation of abnormal connective tissues in various parts of the body. Connective tissues are the structural materials that support and bind other tissues and organs together. They include tendons, ligaments, cartilage, fat, and the material that fills the spaces between cells, called the extracellular matrix.

Connective tissue diseases can affect many different systems in the body, including the skin, joints, muscles, lungs, kidneys, gastrointestinal tract, and blood vessels. Some CTDs are autoimmune disorders, meaning that the immune system mistakenly attacks healthy connective tissues. Others may be caused by genetic mutations or environmental factors.

Some examples of connective tissue diseases include:

* Systemic lupus erythematosus (SLE)
* Rheumatoid arthritis (RA)
* Scleroderma
* Dermatomyositis/Polymyositis
* Mixed Connective Tissue Disease (MCTD)
* Sjogren's syndrome
* Ehlers-Danlos syndrome
* Marfan syndrome
* Osteogenesis imperfecta

The specific symptoms and treatment of connective tissue diseases vary depending on the type and severity of the condition. Treatment may include medications to reduce inflammation, suppress the immune system, or manage pain. In some cases, surgery may be necessary to repair or replace damaged tissues or organs.

Juvenile arthritis (JA) is a term used to describe a group of autoimmune and inflammatory disorders that can affect children aged 16 or younger. In JA, the immune system mistakenly attacks the body's own tissues, causing inflammation in the joints, which can lead to pain, swelling, stiffness, and damage over time.

There are several types of juvenile arthritis, including:

1. Juvenile Idiopathic Arthritis (JIA): This is the most common form of JA, and it includes several subtypes that are classified based on the number of joints affected and the presence or absence of certain symptoms.
2. Juvenile Systemic Lupus Erythematosus (JSLE): This is a type of lupus that affects children, and it can cause inflammation in various parts of the body, including the joints, skin, kidneys, and lungs.
3. Juvenile Dermatomyositis (JDM): This is a rare autoimmune disorder that causes inflammation of the blood vessels, leading to muscle weakness, skin rashes, and joint pain.
4. Juvenile Scleroderma: This is a group of disorders that cause hardening and tightening of the skin and connective tissues, which can also affect the joints.
5. Juvenile Psoriatic Arthritis (JPsA): This is a type of arthritis that affects children who have psoriasis, a chronic skin condition. JPsA can cause inflammation in the joints and skin.

The causes of juvenile arthritis are not fully understood, but it is believed to involve a combination of genetic and environmental factors. There is no cure for JA, but treatments such as medication, physical therapy, and lifestyle changes can help manage the symptoms and prevent long-term complications.

Autoimmune diseases are a group of disorders in which the immune system, which normally protects the body from foreign invaders like bacteria and viruses, mistakenly attacks the body's own cells and tissues. This results in inflammation and damage to various organs and tissues in the body.

In autoimmune diseases, the body produces autoantibodies that target its own proteins or cell receptors, leading to their destruction or malfunction. The exact cause of autoimmune diseases is not fully understood, but it is believed that a combination of genetic and environmental factors contribute to their development.

There are over 80 different types of autoimmune diseases, including rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, psoriasis, and inflammatory bowel disease. Symptoms can vary widely depending on the specific autoimmune disease and the organs or tissues affected. Treatment typically involves managing symptoms and suppressing the immune system to prevent further damage.

Arthritis is a medical condition characterized by inflammation in one or more joints, leading to symptoms such as pain, stiffness, swelling, and reduced range of motion. There are many different types of arthritis, including osteoarthritis, rheumatoid arthritis, psoriatic arthritis, gout, and lupus, among others.

Osteoarthritis is the most common form of arthritis and is caused by wear and tear on the joints over time. Rheumatoid arthritis, on the other hand, is an autoimmune disorder in which the body's immune system mistakenly attacks the joint lining, causing inflammation and damage.

Arthritis can affect people of all ages, including children, although it is more common in older adults. Treatment for arthritis may include medications to manage pain and reduce inflammation, physical therapy, exercise, and in some cases, surgery.

Antirheumatic agents are a class of drugs used to treat rheumatoid arthritis, other inflammatory types of arthritis, and related conditions. These medications work by reducing inflammation in the body, relieving symptoms such as pain, swelling, and stiffness in the joints. They can also help slow down or prevent joint damage and disability caused by the disease.

There are several types of antirheumatic agents, including:

1. Nonsteroidal anti-inflammatory drugs (NSAIDs): These medications, such as ibuprofen and naproxen, reduce inflammation and relieve pain. They are often used to treat mild to moderate symptoms of arthritis.
2. Corticosteroids: These powerful anti-inflammatory drugs, such as prednisone and cortisone, can quickly reduce inflammation and suppress the immune system. They are usually used for short-term relief of severe symptoms or in combination with other antirheumatic agents.
3. Disease-modifying antirheumatic drugs (DMARDs): These medications, such as methotrexate and hydroxychloroquine, work by slowing down the progression of rheumatoid arthritis and preventing joint damage. They can take several weeks or months to become fully effective.
4. Biologic response modifiers (biologics): These are a newer class of DMARDs that target specific molecules involved in the immune response. They include drugs such as adalimumab, etanercept, and infliximab. Biologics are usually used in combination with other antirheumatic agents for patients who have not responded to traditional DMARD therapy.
5. Janus kinase (JAK) inhibitors: These medications, such as tofacitinib and baricitinib, work by blocking the action of enzymes called JAKs that are involved in the immune response. They are used to treat moderate to severe rheumatoid arthritis and can be used in combination with other antirheumatic agents.

It is important to note that antirheumatic agents can have significant side effects and should only be prescribed by a healthcare provider who is experienced in the management of rheumatoid arthritis. Regular monitoring and follow-up are essential to ensure safe and effective treatment.

A rheumatic nodule is not a specific medical definition, but rather a descriptive term for a type of nodule that can be found in certain medical conditions. These nodules are typically associated with rheumatoid arthritis (RA), although they can also occur in other diseases such as systemic lupus erythematosus (SLE) and dermatomyositis.

Rheumatic nodules are small, firm, round or oval-shaped lumps that develop under the skin or in certain organs such as the lungs. They can vary in size from a few millimeters to several centimeters in diameter. In RA, these nodules usually appear on the forearms, elbows, fingers, knees, and ankles, although they can occur in other areas of the body as well.

Histologically, rheumatic nodules are characterized by a central area of fibrinoid necrosis surrounded by palisading histiocytes and fibroblasts. They may also contain lymphocytes, plasma cells, and eosinophils. The presence of these nodules is thought to be related to the immune system's response to the underlying disease process, although their exact cause and significance are not fully understood.

It is important to note that rheumatic nodules can also occur in individuals without any known medical condition, and their presence does not necessarily indicate the presence of a specific disease. However, if you notice any new or unusual lumps or bumps on your body, it is always a good idea to consult with a healthcare professional for further evaluation and diagnosis.

Autoantibodies are defined as antibodies that are produced by the immune system and target the body's own cells, tissues, or organs. These antibodies mistakenly identify certain proteins or molecules in the body as foreign invaders and attack them, leading to an autoimmune response. Autoantibodies can be found in various autoimmune diseases such as rheumatoid arthritis, lupus, and thyroiditis. The presence of autoantibodies can also be used as a diagnostic marker for certain conditions.

Systemic Scleroderma, also known as Systemic Sclerosis (SSc), is a rare, chronic autoimmune disease that involves the abnormal growth and accumulation of collagen in various connective tissues, blood vessels, and organs throughout the body. This excessive collagen production leads to fibrosis or scarring, which can cause thickening, hardening, and tightening of the skin and damage to internal organs such as the heart, lungs, kidneys, and gastrointestinal tract.

Systemic Scleroderma is characterized by two main features: small blood vessel abnormalities (Raynaud's phenomenon) and fibrosis. The disease can be further classified into two subsets based on the extent of skin involvement: limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc).

Limited cutaneous systemic sclerosis affects the skin distally, typically involving fingers, hands, forearms, feet, lower legs, and face. It is often associated with Raynaud's phenomenon, calcinosis, telangiectasias, and pulmonary arterial hypertension.

Diffuse cutaneous systemic sclerosis involves more extensive skin thickening and fibrosis that spreads proximally to affect the trunk, upper arms, thighs, and face. It is commonly associated with internal organ involvement, such as interstitial lung disease, heart disease, and kidney problems.

The exact cause of Systemic Scleroderma remains unknown; however, it is believed that genetic, environmental, and immunological factors contribute to its development. There is currently no cure for Systemic Scleroderma, but various treatments can help manage symptoms, slow disease progression, and improve quality of life.

Rheumatoid factor (RF) is an autoantibody, specifically an immunoglobulin M (IgM) antibody, that can be detected in the blood serum of some people with rheumatoid arthritis (RA), other inflammatory conditions, and infectious diseases. RF targets the Fc portion of IgG, leading to immune complex formation and subsequent inflammation, which contributes to the pathogenesis of RA. However, not all patients with RA test positive for RF, and its presence does not necessarily confirm a diagnosis of RA. Other conditions can also lead to elevated RF levels, such as infections, liver diseases, and certain malignancies. Therefore, the interpretation of RF results should be considered alongside other clinical, laboratory, and imaging findings for an accurate diagnosis and appropriate management.

Sjögren's syndrome is a chronic autoimmune disorder in which the body's immune system mistakenly attacks its own moisture-producing glands, particularly the tear and salivary glands. This can lead to symptoms such as dry eyes, dry mouth, and dryness in other areas of the body. In some cases, it may also affect other organs, leading to a variety of complications.

There are two types of Sjögren's syndrome: primary and secondary. Primary Sjögren's syndrome occurs when the condition develops on its own, while secondary Sjögren's syndrome occurs when it develops in conjunction with another autoimmune disease, such as rheumatoid arthritis or lupus.

The exact cause of Sjögren's syndrome is not fully understood, but it is believed to involve a combination of genetic and environmental factors. Treatment typically focuses on relieving symptoms and may include artificial tears, saliva substitutes, medications to stimulate saliva production, and immunosuppressive drugs in more severe cases.

Psoriatic arthritis is a form of inflammatory arthritis that occurs in some people with psoriasis, a skin condition characterized by scaly, red, and itchy patches. The Arthritis Foundation defines psoriatic arthritis as "a chronic disease characterized by swelling, pain, and stiffness in and around the joints. It usually affects the fingers and toes but can also affect the lower back, knees, ankles, and spine."

Psoriatic arthritis can cause a variety of symptoms, including:

* Joint pain, swelling, and stiffness
* Swollen fingers or toes (dactylitis)
* Tenderness, pain, and swelling where tendons and ligaments attach to bones (enthesitis)
* Changes in nail growth, such as pitting, ridging, or separation from the nail bed
* Fatigue and weakness
* Reduced range of motion and mobility

The exact cause of psoriatic arthritis is not fully understood, but it is believed to involve a combination of genetic, environmental, and immune system factors. Treatment typically involves a combination of medications, lifestyle changes, and physical therapy to manage symptoms and prevent joint damage.

Climatotherapy is a form of therapy that uses a specific climate or weather to treat various medical conditions. This type of therapy involves exposing the patient to a particular climate, such as high altitudes, dry heat, or cold temperatures, in order to achieve therapeutic benefits. The idea behind climatotherapy is that certain climates can have a positive impact on symptoms and overall health.

For example, people with respiratory conditions like asthma or chronic obstructive pulmonary disease (COPD) may benefit from living in a dry, desert climate, as the low humidity can help reduce inflammation and improve lung function. Similarly, those with rheumatoid arthritis or other joint diseases may find relief in warm, mineral-rich waters, such as those found in hot springs or spas.

Climatotherapy is often used as a complementary therapy alongside conventional medical treatments, and its effectiveness can vary depending on the individual and their specific medical condition. It's important to consult with a healthcare provider before starting any new treatment regimen, including climatotherapy.

Spondylitis is a term used to describe inflammation in the spinal vertebrae, often leading to stiffness and pain. The most common form is Ankylosing Spondylitis, which is a chronic autoimmune disease where the body's immune system mistakenly attacks the joints in the spine. This can cause the bones in the spine to grow together, resulting in a rigid and inflexible spine. Other forms of spondylitis include reactive spondylitis, infectious spondylitis, and seronegative spondyloarthropathies. Symptoms may also include pain and stiffness in the neck, lower back, hips, and small joints of the body.

Reactive arthritis is a form of inflammatory arthritis that occurs in response to an infection in another part of the body, such as the genitals, urinary tract, or gastrointestinal tract. It is also known as Reiter's syndrome. The symptoms of reactive arthritis include joint pain and swelling, typically affecting the knees, ankles, and feet; inflammation of the eyes, skin, and mucous membranes; and urethritis or cervicitis. It is more common in men than women and usually develops within 1-4 weeks after a bacterial infection. The diagnosis is made based on the symptoms, medical history, physical examination, and laboratory tests. Treatment typically includes antibiotics to eliminate the underlying infection and medications to manage the symptoms of arthritis.

Antinuclear antibodies (ANA) are a type of autoantibody that target structures found in the nucleus of a cell. These antibodies are produced by the immune system and attack the body's own cells and tissues, leading to inflammation and damage. The presence of ANA is often used as a marker for certain autoimmune diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome, rheumatoid arthritis, scleroderma, and polymyositis.

ANA can be detected through a blood test called the antinuclear antibody test. A positive result indicates the presence of ANA in the blood, but it does not necessarily mean that a person has an autoimmune disease. Further testing is usually needed to confirm a diagnosis and determine the specific type of autoantibodies present.

It's important to note that ANA can also be found in healthy individuals, particularly as they age. Therefore, the test results should be interpreted in conjunction with other clinical findings and symptoms.

Mixed Connective Tissue Disease (MCTD) is a rare overlapping condition of the connective tissues, characterized by the presence of specific autoantibodies against a protein called "U1-snRNP" or "U1-small nuclear ribonucleoprotein." This disorder has features of various connective tissue diseases such as systemic lupus erythematosus (SLE), scleroderma, polymyositis, and rheumatoid arthritis. Symptoms may include swollen hands, joint pain and swelling, muscle weakness, skin thickening, lung involvement, and Raynaud's phenomenon. The exact cause of MCTD is unknown, but it is believed to involve both genetic and environmental factors leading to an autoimmune response. Early diagnosis and treatment are essential for better disease management and preventing severe complications.

Gout is a type of inflammatory arthritis that occurs when urate crystals accumulate in and around the joints, causing sudden attacks of severe pain, swelling, redness, and tenderness. Urate crystals can form when there are high levels of uric acid in the blood. Uric acid is a waste product that is produced when the body breaks down purines, substances that are found naturally in certain foods, such as steak, organ meats, and seafood. Other foods also promote higher levels of uric acid, such as alcoholic beverages, especially beer, and drinks sweetened with fruit sugar (fructose).

Normally, uric acid dissolves in the blood and passes through the kidneys and out of the body in urine. But sometimes either the body produces too much uric acid or the kidneys excrete too little uric acid. When this happens, uric acid can build up, forming sharp, needle-like urate crystals in a joint or surrounding tissue that cause pain, inflammation and swelling.

Gout most commonly affects the big toe but can also occur in any joint in the body. The symptoms of gout are often acute, occurring suddenly without warning and frequently at night. The attacks are characterized by a rapid onset of pain, swelling, warmth, and redness in the affected joint. An attack of gout can be so painful that it wakes you up from sleep.

Over time, gout can cause permanent damage to the joints and surrounding tissue, resulting in chronic arthritis. If left untreated, gout also can lead to an accumulation of uric acid crystals in the kidneys, which can result in kidney stones.

Osteoarthritis (OA) is a type of joint disease that is characterized by the breakdown and eventual loss of cartilage - the tissue that cushions the ends of bones where they meet in the joints. This breakdown can cause the bones to rub against each other, causing pain, stiffness, and loss of mobility. OA can occur in any joint, but it most commonly affects the hands, knees, hips, and spine. It is often associated with aging and can be caused or worsened by obesity, injury, or overuse.

The medical definition of osteoarthritis is: "a degenerative, non-inflammatory joint disease characterized by the loss of articular cartilage, bone remodeling, and the formation of osteophytes (bone spurs). It is often associated with pain, stiffness, and decreased range of motion in the affected joint."

Microscopic angioscopy is not a widely recognized or established medical term. However, based on the individual terms, it can be interpreted as the use of a microscope with an angioscope (a type of endoscope used for visualizing the interior of blood vessels) to examine the microscopic structures of the inner walls of blood vessels. This technique would allow for detailed examination of the vasculature at a cellular level, potentially providing valuable information for research and diagnosis of various vascular diseases. However, as this is not a standard medical procedure or term, it's essential to consult the relevant literature or experts in the field for more precise information.

Synovial fluid is a viscous, clear, and straw-colored fluid found in the cavities of synovial joints, bursae, and tendon sheaths. It is produced by the synovial membrane, which lines the inner surface of the capsule surrounding these structures.

The primary function of synovial fluid is to reduce friction between articulating surfaces, providing lubrication for smooth and painless movement. It also acts as a shock absorber, protecting the joints from external forces during physical activities. Synovial fluid contains nutrients that nourish the articular cartilage, hyaluronic acid, which provides its viscoelastic properties, and lubricin, a protein responsible for boundary lubrication.

Abnormalities in synovial fluid composition or volume can indicate joint-related disorders, such as osteoarthritis, rheumatoid arthritis, gout, infection, or trauma. Analysis of synovial fluid is often used diagnostically to determine the underlying cause of joint pain, inflammation, or dysfunction.

I'm sorry for any confusion, but "Portugal" is not a medical term. It is a country located in southwestern Europe, known officially as the Portuguese Republic. If you have any questions about medical terminology or health-related topics, I would be happy to help!

Spondylarthropathies is a term used to describe a group of interrelated inflammatory diseases that primarily affect the joints of the spine (vertebral column) and the sites where the ligaments and tendons attach to the bones (entheses). These conditions also often have associations with extra-articular features, such as skin, eye, and intestinal manifestations. The most common spondylarthropathies are ankylosing spondylitis, psoriatic arthritis, reactive arthritis (formerly known as Reiter's syndrome), enteropathic arthritis (associated with inflammatory bowel disease), and undifferentiated spondyloarthropathies.

The primary hallmark of these conditions is enthesitis, which is an inflammation at the sites where ligaments or tendons attach to bones. This can lead to pain, stiffness, and limited mobility in the affected areas, particularly in the spine and sacroiliac joints (the joints that connect the base of the spine to the pelvis).

Spondylarthropathies have a strong genetic association with the human leukocyte antigen B27 (HLA-B27) gene. However, not all individuals with this gene will develop spondylarthropathies, and many people without the gene can still be affected by these conditions.

Early diagnosis and appropriate treatment of spondylarthropathies are essential to help manage symptoms, prevent joint damage, and maintain mobility and quality of life. Treatment options typically include a combination of medications, physical therapy, and lifestyle modifications.

Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive difficulties. The pain typically occurs in specific tender points or trigger points, which are located on the neck, shoulders, back, hips, arms, and legs. These points are painful when pressure is applied.

The exact cause of fibromyalgia is unknown, but it appears to be related to abnormalities in the way the brain processes pain signals. It may also be associated with certain genetic factors, physical trauma, infection, or emotional stress. Fibromyalgia is more common in women than men and tends to develop between the ages of 20 and 50.

Fibromyalgia can be difficult to diagnose because its symptoms are similar to those of other conditions, such as rheumatoid arthritis, lupus, and chronic fatigue syndrome. However, a diagnosis of fibromyalgia may be made if a person has widespread pain for at least three months and tenderness in at least 11 of 18 specific points on the body when pressure is applied.

There is no cure for fibromyalgia, but medications, therapy, and lifestyle changes can help manage its symptoms. Treatment may include pain relievers, antidepressants, anti-seizure drugs, physical therapy, counseling, stress reduction techniques, and regular exercise.

Health Planning Organizations (HPOs) are entities that are responsible for planning, coordinating, and evaluating health services within a specific geographic area. The primary goal of HPOs is to ensure the delivery of high-quality, cost-effective healthcare services that meet the needs of the population they serve.

HPOs may be involved in various activities, including:

1. Needs assessment: Identifying the health needs and priorities of the population, including any disparities or inequities in access to care.
2. Resource allocation: Deciding how to allocate resources to address identified needs and priorities.
3. Service planning: Developing plans for the delivery of healthcare services that are evidence-based, efficient, and effective.
4. Quality improvement: Monitoring and evaluating the quality of healthcare services and implementing strategies to improve them.
5. Coordination: Coordinating the delivery of healthcare services across different providers and settings to ensure continuity of care.
6. Advocacy: Advocating for policies and practices that promote health equity, access to care, and improved health outcomes.

HPOs can take various forms, including local health departments, regional health authorities, hospital networks, and other types of collaborative entities. They may be public or private, non-profit or for-profit, and their governance structures and funding mechanisms can vary widely.

Overall, the role of HPOs is to ensure that healthcare services are designed and delivered in a way that meets the needs of the population, improves health outcomes, and promotes health equity.

Vasculitis is a group of disorders characterized by inflammation of the blood vessels, which can cause changes in the vessel walls including thickening, narrowing, or weakening. These changes can restrict blood flow, leading to organ and tissue damage. The specific symptoms and severity of vasculitis depend on the size and location of the affected blood vessels and the extent of inflammation. Vasculitis can affect any organ system in the body, and its causes can vary, including infections, autoimmune disorders, or exposure to certain medications or chemicals.

Polymyalgia Rheumatica (PMR) is a geriatric rheumatic disease characterized by widespread musculoskeletal pain and stiffness, particularly affecting the neck, shoulders, hips, and thighs. It is often accompanied by symptoms such as fatigue, weakness, loss of appetite, and low-grade fever. The onset of PMR can be sudden or gradual, and it tends to affect individuals over 50 years of age, more commonly women than men.

The exact cause of Polymyalgia Rheumatica remains unknown; however, it is believed to involve an autoimmune response leading to inflammation in the affected areas. Diagnosis typically involves a combination of clinical evaluation, laboratory tests (such as elevated erythrocyte sedimentation rate or C-reactive protein), and sometimes imaging studies. Treatment usually includes corticosteroids to reduce inflammation and manage symptoms, along with monitoring for potential side effects from long-term steroid use. In many cases, PMR can be successfully managed with appropriate treatment, allowing individuals to return to their normal activities.

HLA-B27 antigen is a type of human leukocyte antigen (HLA) found on the surface of white blood cells. HLAs are proteins that help the body's immune system distinguish its own cells from foreign substances such as viruses and bacteria.

HLA-B27 is a specific type of HLA-B antigen, which is part of the major histocompatibility complex (MHC) class I molecules. The presence of HLA-B27 antigen can be inherited from parents to their offspring.

While most people with the HLA-B27 antigen do not develop any health problems, this antigen is associated with an increased risk of developing certain inflammatory diseases, particularly spondyloarthritis, a group of disorders that affect the joints and spine. Examples of these conditions include ankylosing spondylitis, reactive arthritis, psoriatic arthritis, and enteropathic arthritis associated with inflammatory bowel disease. However, not everyone with HLA-B27 will develop these diseases, and many people without the antigen can still develop spondyloarthritis.

Chorea is a medical term that describes an involuntary movement disorder characterized by brief, irregular, and abrupt jerky movements. These movements often occur randomly and can affect any part of the body. Chorea can also cause difficulty with coordination and balance, and can sometimes be accompanied by muscle weakness or rigidity.

The term "chorea" comes from the Greek word "χορεία" (khoréia), which means "dance," reflecting the graceful, dance-like movements that are characteristic of this condition. Chorea can occur as a symptom of various underlying medical conditions, including neurological disorders such as Huntington's disease, Sydenham's chorea, and cerebral palsy, as well as metabolic disorders, infections, and certain medications.

Treatment for chorea depends on the underlying cause of the condition and may include medications to help control the involuntary movements, physical therapy to improve coordination and balance, and lifestyle modifications to reduce the risk of injury from falls or other accidents. In some cases, surgery may be recommended as a last resort for severe or refractory chorea.

Polymyositis is defined as a rare inflammatory disorder that causes muscle weakness and inflammation (swelling) of the muscles. It primarily affects the skeletal muscles, which are the muscles responsible for voluntary movements such as walking, talking, and swallowing. The onset of polymyositis can occur at any age but is most commonly seen in adults between 31 to 60 years old, with women being slightly more affected than men.

The exact cause of polymyositis remains unknown; however, it is believed to be an autoimmune disorder, where the body's immune system mistakenly attacks its own muscle tissue. Certain factors such as genetics, viral infections, and exposure to certain drugs may contribute to the development of this condition.

Polymyositis can cause various symptoms, including:
- Progressive muscle weakness and wasting, particularly affecting the proximal muscles (those closest to the trunk of the body) such as the hips, thighs, shoulders, and upper arms.
- Difficulty climbing stairs, lifting objects, or rising from a seated position.
- Fatigue and stiffness, especially after periods of inactivity.
- Joint pain and swelling.
- Difficulty swallowing or speaking.
- Shortness of breath due to weakened respiratory muscles.

Diagnosis of polymyositis typically involves a combination of medical history, physical examination, laboratory tests, electromyography (EMG), and muscle biopsy. Treatment usually includes medications such as corticosteroids and immunosuppressants to reduce inflammation and control the immune response. Physical therapy may also be recommended to help maintain muscle strength and flexibility.

If left untreated, polymyositis can lead to significant disability and complications, including respiratory failure, malnutrition, and cardiovascular disease. Early diagnosis and treatment are crucial for improving outcomes and preventing long-term complications.

Myositis is a medical term that refers to inflammation of the muscle tissue. This condition can cause various symptoms, including muscle weakness, pain, swelling, and stiffness. There are several types of myositis, such as polymyositis, dermatomyositis, and inclusion body myositis, which have different causes and characteristics.

Polymyositis is a type of myositis that affects multiple muscle groups, particularly those close to the trunk of the body. Dermatomyositis is characterized by muscle inflammation as well as a skin rash. Inclusion body myositis is a less common form of myositis that typically affects older adults and can cause both muscle weakness and wasting.

The causes of myositis vary depending on the type, but they can include autoimmune disorders, infections, medications, and other medical conditions. Treatment for myositis may involve medication to reduce inflammation, physical therapy to maintain muscle strength and flexibility, and lifestyle changes to manage symptoms and prevent complications.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

According to the United States Food and Drug Administration (FDA), biological products are "products that are made from or contain a living organism or its derivatives, such as vaccines, blood and blood components, cells, genes, tissues, and proteins." These products can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, and they can come from many sources, including humans, animals, microorganisms, or plants.

Biological products are often used to diagnose, prevent, or treat a wide range of medical conditions, and they can be administered in various ways, such as through injection, inhalation, or topical application. Because biological products are derived from living organisms, their manufacturing processes can be complex and must be tightly controlled to ensure the safety, purity, and potency of the final product.

It's important to note that biological products are not the same as drugs, which are chemically synthesized compounds. While drugs are designed to interact with specific targets in the body, such as enzymes or receptors, biological products can have more complex and varied mechanisms of action, making them potentially more difficult to characterize and regulate.

The Annals of the Rheumatic Diseases is a monthly peer-reviewed medical journal. It is published by the BMJ Group on behalf of ... The journal has been cited most often by: Arthritis & Rheumatism, Annals of the Rheumatic Diseases, Rheumatology, Journal of ... Journal homepage "Annals of the Rheumatic Diseases". 2022 Journal Citation Reports. Web of Science (Science OR Social Sciences ... The journals it has cited most are Arthritis & Rheumatism, Annals of the Rheumatic Diseases, Journal of Rheumatology, ...
... is a medical journal addressing topics in rheumatology. Best Practice & Research: ...
The Royal National Hospital for Rheumatic Diseases is a small, specialist NHS hospital on the Royal United Hospital (RUH) site ... It was announced in January 2015 that the Royal National Hospital for Rheumatic Diseases NHS Foundation Trust would be taken ... Official website RNHRD art collection - Art at the RUH The Royal National Hospital for Rheumatic Diseases National Health ... In 2003, the hospital became an NHS Foundation Trust, specialising in rheumatic disease and rehabilitation, which received a ...
... as a joint project between WHO and ILAR. COPCORD promotes low cost ... epidemiological research in developing countries and has contributed to the understanding of disease burden in data poor ...
"Morris Ziff Dies at 91; Rheumatic Disease Expert". The New York Times. August 30, 2005. Retrieved May 6, 2015. Oransky, Ivan ( ... educator and researcher specializing in arthritic and rheumatic disorders, possibly best known for helping discover the ...
She contributed to a number of papers on rheumatic and coronary artery diseases by Carey Coombs, including the 1926 Long Fox ... Coombs, Carey Franklin (November 1924). Rheumatic Heart Disease. Frederic John Poynton. Bristol: John Wright and Sons. OCLC ... Coates, Vincent; Coombs, Carey Franklin (January 1926). "Observations on the Rheumatic Nodule". Archives of Disease in ... Disease and the Art of Medical Illustration. Wellcome Collection. London: Thames and Hudson. ISBN 978-0-500-51734-5. OCLC ...
"Arthritis and Rheumatic Diseases". NIAMS. October 2014. Archived from the original on 4 October 2016. Retrieved 31 March 2021 ... Lyme disease Sjögren's disease Hashimoto's thyroiditis Celiac disease Non-celiac gluten sensitivity Inflammatory bowel disease ... There is no known cure for arthritis and rheumatic diseases. Treatment options vary depending on the type of arthritis and ... They are all types of rheumatic disease. Treatment may include resting the joint and alternating between applying ice and heat ...
Theodoridou A, Settas L (2006). "Demyelination in rheumatic diseases". J. Neurol. Neurosurg. Psychiatry. 77 (989): 290-5. doi: ... It is also thought that WMH have a negative impact on cognition in people with Alzheimer's disease. In people with Alzheimer's ... Molecular Basis of Disease. 1822 (3): 361-369. doi:10.1016/j.bbadis.2011.08.007. PMC 3245802. PMID 21889590. Van Der Flier, W M ... Alzheimer's disease risk, and cognitive function". Neurobiology of Aging. 35 (4): 769-776. doi:10.1016/j.neurobiolaging.2013.10 ...
... rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic ... heart disease) and lungs (lung disease). Cardiovascular disease - (CVD), is a class of diseases that involve the heart or blood ... Coeliac disease - Coeliac disease or celiac disease is a long-term autoimmune disorder that primarily affects the small ... to correct congenital heart disease; or to treat valvular heart disease from various causes, including endocarditis, rheumatic ...
Talsania M, Scofield RH (May 2017). "Menopause and rheumatic disease". Rheumatic Disease Clinics of North America (Review). 43 ... Although anovulation is not considered a disease, it can be a sign of an underlying condition such as polycystic ovary syndrome ... Disease Models. 32, Part B: 31-40. doi:10.1016/j.ddmod.2020.11.005. Simmons RG, Jennings V (July 2020). "Fertility awareness- ... the changes in hormone levels during the menstrual cycle can increase the incidence of disorders such as autoimmune diseases, ...
Lambova, Sevdalina Nikolova (10 February 2023). "Microangiopathy in Rheumatic Diseases". Life. 13 (2): 491. doi:10.3390/ ... Microangiopathy (also known as microvascular disease, small vessel disease (SVD) or microvascular dysfunction) is a disease of ... it has been employed in non-rheumatic diseases with microvascular involvement such as diabetes mellitus, essential hypertension ... chronic kidney disease, chronic venous insufficiency, systemic scleroderma and other connective tissue diseases (CTDs) ...
Amis AA, Miller JH (December 1982). "The elbow". Clinics in Rheumatic Diseases. 8 (3): 571-93. doi:10.1016/S0307-742X(21)00409- ... that enable males to develop impressive ornaments or fighting ability may be correlated with fitness markers such as disease ...
Utsinger PD (August 1985). "Diffuse idiopathic skeletal hyperostosis". Clinics in Rheumatic Diseases. 11 (2): 325-51. doi: ... The disease can spread to any joint of the body, affecting the neck, shoulders, ribs, hips, pelvis, knees, ankles, and hands. ... Classically, advanced disease may have "melted candle wax" appearance along the spine on radiographic studies. In some cases, ... The disease is not fatal; however, some associated complications can lead to death. Complications may include paralysis, ...
He is a co-author of the book, "The Clinical Neurology of Rheumatic Diseases". Rosenbaum is a National Merit Scholar who ... Previously, he was Chief of Arthritis and Rheumatic Diseases at the Oregon Health & Science University where he held the Edward ... "James T. Rosenbaum, M.D. , Arthritis & Rheumatic Diseases (Adult) , OHSU". Ohsu.edu. Archived from the original on 2013-11-07. ... Lahita, Robert G. (1997). "Book Review Clinical Neurology of Rheumatic Diseases by Richard B. Rosenbaum, Stephen M. Campbell, ...
Annals of the Rheumatic Diseases. 65 (6): 753-759. doi:10.1136/ard.2005.044404. PMC 1798163. PMID 16308341. Schendel, D.J.; ... "Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with ...
Primer on the Rheumatic Diseases. Springer. p. 80. ISBN 9780387356648. McAfee, JH; Smith, DL (November 1988). "Olecranon and ... and chronic obstructive pulmonary disease.: p. 22 Some cases are idiopathic, though these may be caused by trauma that the ... Occupational diseases, Overuse injuries, Soft tissue disorders, Knee injuries and disorders). ...
Bywaters, E. G. L. (March 1971). "Still's disease in the adult". Annals of the Rheumatic Diseases. 30 (2): 121-33. doi:10.1136/ ... Bywaters characterises adult-onset Still's disease, a rare form of inflammatory arthritis. Smallpox is eradicated from the ...
Annals of the Rheumatic Diseases. 69 (8): 1459-64. doi:10.1136/ard.2009.120469. PMC 3086604. PMID 20525840. Barnhill, JG; Fye, ... Annals of the Rheumatic Diseases. 67 (6): 735-40. doi:10.1136/ard.2006.068882. PMID 17644553. S2CID 41984358. Conte, A; ... It is also approved and regulated as a symptomatic slow-acting drug for this disease (SYSADOA) in Europe and some other ... Chondroitin has shown to be promising in the treatment of coronary artery disease. In a 6-year double-blind placebo-controlled ...
Forbess, L; Bannykh, S (2015). "Polyarteritis Nodosa". Rheumatic Disease Clinics of North America. 41 (1): 33-46, vii. doi: ... The medical eponyms Kussmaul disease or Kussmaul-Maier disease reflect the seminal description of the disease in the medical ... Annals of the Rheumatic Diseases. 69 (5): 785-86. doi:10.1136/ard.2009.127886. PMID 20388739. "Log in , BMJ Best Practice". ... Untreated, the disease is fatal in most cases. The most serious associated conditions generally involve the kidneys and ...
Annals of the Rheumatic Diseases. 62 (1): 20-26. doi:10.1136/ard.62.1.20. PMC 1754293. PMID 12480664. McKenna, Stephen (2011). ... International Journal of Rheumatic Disease. 13 (4): 361-366. doi:10.1111/j.1756-185X.2010.01554.x. PMID 21199471. Doward, Lynda ... Annals of the Rheumatic Diseases. 62 (10): 1020-1021. doi:10.1136/ard.62.10.1020. PMC 1754338. PMID 12972490. Jenks, Katherine ... disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing ...
Annals of the Rheumatic Diseases. 41 (4): 382-387. doi:10.1136/ard.41.4.382. PMC 1000955. PMID 7051989. Lodi, Gianluca; Resca, ... "Cold agglutinin disease". Genetic and Rare Diseases Information Center (GARD) - an NCATS Program. 2015-09-11. Archived from the ... chronic inflammatory diseases (such as autoimmune disease); and/or cancers of the blood or immune system. Treatment varies ... both of which are sole two subtypes of cold agglutinin disease. Primary cold agglutinin disease is idiopathic, meaning the ...
Annals of the Rheumatic Diseases. 73 (Suppl 2): 1103-1104. doi:10.1136/annrheumdis-2014-eular.3697. ISSN 0003-4967. S2CID ... It is a very rare genetic disease. It is characterized by an elevated level of immunoglobulin D in the blood. Mevalonate kinase ... Mevalonic aciduria at NIH's Office of Rare Diseases (Wikipedia articles with style issues from October 2021, All articles with ... This categorises the condition as a rare genetic disease. Mevalonic acid Online Mendelian Inheritance in Man (OMIM): 251170 " ...
October 2022). "Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and ... Annals of the Rheumatic Diseases. 81 (10): 1344-1347. doi:10.1136/ard-2022-223016. PMID 35961760. S2CID 251540204. Dawes M, ... Medicine has a long history of scientific inquiry about the prevention, diagnosis, and treatment of human disease. In the 11th ... and co-morbid diseases), evidence from RCTs may not be generalizable to those populations. Thus, EBM applies to groups of ...
Annals of the Rheumatic Diseases. 51 (3): 313-317. doi:10.1136/ard.51.3.313. PMC 1004650. PMID 1374227. Gerard NP, Garraway LA ... Other diseases in which the NK1 receptor system is involved include asthma, rheumatoid arthritis and gastrointestinal disorders ... "Substance P and substance P receptor histochemistry in human neurodegenerative diseases". Regulatory Peptides. 46 (1-2): 174- ...
Primer on the rheumatic diseases. Atlanta, GA: Arthritis Foundation. ISBN 978-0-912423-29-6. Ushiki T (2002). "Collagen fibers ... Adult linear IgA disease Bullous pemphigoid Bullous lupus erythematosus Childhood linear IgA disease (chronic bullous disease ... Weil's disease) Listeriosis Ludwig's angina Lupoid sycosis Lyme disease (Afzelius' disease, Lyme borreliosis) Lymphogranuloma ... Haxthausen's disease) Keratosis punctata palmaris et plantaris (Buschke-Fischer-Brauer disease, Davis Colley disease, ...
Annals of the Rheumatic Diseases. 59 (9): 700-4. doi:10.1136/ard.59.9.700. PMC 1753277. PMID 10976083. v t e (Articles needing ...
Annals of the Rheumatic Diseases. 82 (Suppl 1): 1025-1026. doi:10.1136/annrheumdis-2023-eular.2454. ISSN 0003-4967. Sprifermin ... Annals of the Rheumatic Diseases. 80 (8): 1062-1069. doi:10.1136/annrheumdis-2020-219181. PMC 8292562. PMID 33962962. Eckstein ... Annals of the Rheumatic Diseases. 80 (8): 1062-1069. doi:10.1136/annrheumdis-2020-219181. PMC 8292562. PMID 33962962. Conaghan ... These findings suggest significant potential of FGF18 as a disease modifying drug for the treatment of OA (DMOAD) and warrant ...
... further evidence of increased predisposition to immune diseases". Annals of the Rheumatic Diseases. 69 (1): 309-11. doi:10.1136 ... Annals of the Rheumatic Diseases. 69 (8): 1471-4. doi:10.1136/ard.2009.114934. PMC 2938883. PMID 19734133. Burton, Paul R.; ... "Autoimmune disease association signals in CIITA and KIAA0350 are not involved in celiac disease susceptibility". Tissue ... June 2007). "Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls". Nature. 447 ( ...
"The Pan-American League for the Study and Control of Rheumatic Diseases". Annals of the Rheumatic Diseases. 4 (3): 69-70. doi: ... Overall, PANLAR is committed to improving the quality of life for people with rheumatic diseases in the Americas through ... the Pan-American League for the Study and Control of Rheumatic Disease came into existence. A few days later, its name would be ... and courses for healthcare professionals involved in the care of patients with rheumatic diseases. These events aim to provide ...
Jawad AS (June 1987). "Alternatives to allopurinol". Annals of the Rheumatic Diseases. 46 (6): 493. doi:10.1136/ard.46.6.493-a ...
Rheumatic fever is an inflammatory condition that can develop if strep throat, scarlet fever, and strep skin infections are not ... If rheumatic fever is not treated promptly, rheumatic heart disease may occur. Rheumatic heart disease weakens the valves ... Rheumatic fever (acute rheumatic fever) is a condition that can affect the heart, joints, brain, and skin. Rheumatic fever can ... People who develop rheumatic heart disease (long-term heart damage) with symptoms of heart failure may require medicines to ...
The Annals of the Rheumatic Diseases is a monthly peer-reviewed medical journal. It is published by the BMJ Group on behalf of ... The journal has been cited most often by: Arthritis & Rheumatism, Annals of the Rheumatic Diseases, Rheumatology, Journal of ... Journal homepage "Annals of the Rheumatic Diseases". 2022 Journal Citation Reports. Web of Science (Science OR Social Sciences ... The journals it has cited most are Arthritis & Rheumatism, Annals of the Rheumatic Diseases, Journal of Rheumatology, ...
Pregnancy in Rheumatic Disease Quadruples Risk of Cardiovascular Events * Pregnancies With Low Anti-SSA/Ro Autoantibody Levels ... Pregnancy in Rheumatic Disease Quadruples Risk of Cardiovascular Events - Medscape - Nov 12, 2023. ... SAN DIEGO, California - Pregnant individuals with autoimmune rheumatic diseases (ARDs) are at least four times more likely to ... Although the study grouped rheumatic diseases together, "lupus is generally driving these results," Sharon Kolasinski, MD, of ...
Rheumatic heart disease is the most serious complication of rheumatic fever. Acute rheumatic fever follows 0. ... Rheumatic heart disease is the most serious complication of rheumatic fever. Acute rheumatic fever and rheumatic heart disease ... Drugs & Diseases , Pediatrics: Cardiac Disease and Critical Care Medicine Pediatric Rheumatic Heart Disease. Updated: Dec 01, ... Association of rheumatic fever & rheumatic heart disease with plausible early & late-stage disease markers. Indian J Med Res. ...
... due to one or more episodes of rheumatic fever. Learn more here. ... Rheumatic heart disease is a condition where the heart valves ...
Guidance was needed for which tests to use for screening and monitoring this particular disease, said lead author Sindhu R. ... in patients with systemic autoimmune rheumatic disease.. The recommendations apply to adults with rheumatic diseases at greater ... "Interstitial lung disease is a major cause of morbidity and mortality across several systemic autoimmune rheumatic diseases," ... More clinical data on ILD in patients with rheumatic disease would help strengthen evidence, she said, particularly for best ...
Copyright © 2023 BMJ Publishing Group Ltd & European Alliance of Associations for Rheumatism. All rights reserved. ...
European Alliance of Associations for Rheumatology, EULAR 2023. Published by BMJ. All rights reserved.. ...
... disease diagnosis, assessment of disease risk, evaluation of disease course and treatment responses; (2) To conduct early phase ... BIOMARKERS FOR RHEUMATIC AND SKIN DISEASES Release Date: January 29, 2001 NOTICE: NOT-AR-01-004 RFP AVAILABLE: NIH-NIAMS-BAA-01 ... in the biology and pathogenesis of rheumatic and skin diseases that directly leads to development, characterization and testing ... evaluate biochemical/biological markers to assess rheumatic and skin disease risk, onset, progression and response to treatment ...
... the most common acquired heart disease in children in many countries of the world - is being neglected and poorly treated, ... for reducing morbidity and mortality in rheumatic heart disease. REMEDY seeks to put an end to rheumatic heart disease in our ... and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the Remedy ... Rheumatic heart disease (RHD) -- the most common acquired heart disease in children in many countries of the world -- is being ...
... disease outcomes and medication safety among children with diverse pediatric rheumatologist diseases. The Registry also intends ... Pediatric rheumatology diseases include juvenile arthritis, systemic lupus erythematosus, scleroderma and juvenile ... to better understand the biology of these diseases. The CARRA Registry aims to make it possible for all affected children in ... Registry is an international registry of children and young adults with pediatric-onset rheumatic conditions such as juvenile ...
Division of Rheumatic Diseases Message from the Director of the Department. In the Division of Rheumatic Diseases, we provide ... Diabetes and Endocrine Diseases and Division of Rheumatic Diseases treats a wide range of diseases from common diseases ... Scope of Target Diseases. The Division of Rheumatic Diseases provides specialized care for various rheumatic and collagen ... Division of Kidney, Diabetes and Endocrine Diseases. Division of Rheumatic Diseases. Department of Cardiovascular Medicine. ...
Disease-modifying anti-rheumatic drugs (DMARDs) for Sjogrens syndrome. This is a protocol for a Cochrane Review (intervention ... Gualtierotti R, Rota M, Lopez-Olivo MA, Spadari F, La Vecchia C, Cugno M. Disease-modifying anti-rheumatic drugs (DMARDs) for ...
Legg-Calvé-Perthes Disease, Osgood-Schlatter Disease, Severs Disease, Freibergs disease, Scheuermanns disease ... Rheumatic Fever And Post-streptococcal Reactive Arthritis Autoinflammatory Diseases Blau, CANDLE, CAPS, CRMO, DIRA, FMF, Majeed ...
Legg-Calvé-Perthes Disease, Osgood-Schlatter Disease, Severs Disease, Freibergs disease, Scheuermanns disease ... Rheumatic Fever And Post-streptococcal Reactive Arthritis Autoinflammatory Diseases Blau, CANDLE, CAPS, CRMO, DIRA, FMF, Majeed ...
NACCHO, acknowledges the Traditional Owners of this land which continues to be under their ongoing custodianship. We pay our respect to Elders past, present and emerging ...
National Rheumatic Heart Disease Data Collection page on the Australian Institute of Health and Welfare website ... National Rheumatic Heart Disease Data Collection. Print this page Click to open the social media sharing options Share Share ... comprises information from jurisdictional registers of notified cases of acute rheumatic fever/rheumatic heart disease (ARF/RHD ... The National Rheumatic Heart Disease Data Collection (NRHDDC) ... What is Rheumatic heart disease Rheumatic heart disease and ...
The Deadly Link: Strep Throat and Rheumatic Heart Disease (RHD). * The Fight For Children Sports Medicine Center Innovative ... The link between untreated strep throat infections and the heart damage of rheumatic heart disease (RHD) is truly deadly. Learn ... Craig Sable, M.D., aims to reduce the global burden of rheumatic heart disease ... Celiac Disease: Getting Started on a Gluten Free Diet. * Risk of Gluten Cross-Contact in Shared Kitchens and School ...
Quality and continuity of care in Dutch nurse clinics for people with rheumatic diseases.. Temmink, D., Hutten, J.B.F., Francke ... Objective: recently a new form of nurse clinic for people with rheumatic diseases has been introduced into Dutch health care. ... Objective: recently a new form of nurse clinic for people with rheumatic diseases has been introduced into Dutch health care. ... Quality and continuity of care in Dutch nurse clinics for people with rheumatic diseases. International Journal for Quality in ...
Immunological Consequences of COVID-19 Vaccination in Patients with Rheumatic Diseases. Overview. Tab Title Description ... This research trial will study the immune respone to COVID-19 vaccination in patients with rheumatic diseases. ... Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ... uses historical information collected from medical records of large groups of people to study how diseases progress and which ...
... ... Joan Wither is a world-renowned Senior Scientist focused on autoimmune rheumatic disease. Her research and basic science ... She discusses the importance of studying patients at various points throughout the disease, whether in a disease-dormant or ... researching systematic autoimmune rheumatic diseases.. A healthy immune system is ready to fight the body against any potential ...
All 30 neuropsychiatric symptoms included were significantly higher in patients with systemic autoimmune rheumatic diseases ... Neuropsychiatric Symptoms in Rheumatic Disease Greatly Underestimated by Clinicians .social-ris-container { display: flex; ... All 30 neuropsychiatric symptoms included were significantly higher in patients with systemic autoimmune rheumatic diseases ... Prevalence and identification of neuropsychiatric symptoms in systemic autoimmune rheumatic diseases: an international mixed ...
Bacteremia and Rheumatic Symptoms in Patients from Lyme Disease-endemic Region. Emerging Infectious Diseases, 18(11), 1919-1921 ... Bacteremia and Rheumatic Symptoms in Patients from Lyme Disease-endemic Region. Emerging Infectious Diseases. 2012;18(11):1919- ... bacteremia and rheumatic symptoms in patients from Lyme disease-endemic region. Emerg Infect Dis. 2012;18:783-91. DOIPubMed ... bacteremia and rheumatic symptoms in patients from Lyme disease-endemic region [letter]. Emerg Infect Dis. 2012;18:1918-9. ...
... describing reactivation in patients on immunosuppressive therapies for the treatment of autoimmune rheumatic diseases. We ... Reactivation of Chagas disease has been described in immunosuppressed patients, but there is a paucity of literature ... describe a case of Chagas disease reactivation in a woman tak … ... Disease in a Patient With an Autoimmune Rheumatic Disease: Case ... 3 Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. ...
Management of Atherosclerotic Carotid and Vertebral Artery Disease Guidelines. Take Quiz. Chronic Kidney Disease Treatment. ... Lyme Disease Prevention, Diagnosis, and Treatment. Take Quiz. HIV treatment considerations for men who have sex with women. ... Cardiovascular disease risk and high testosterone in postmenopausal women. Take Quiz. Vulvovaginitis: Diagnosis & management. ... Genetic factors in autosomal dominant polycystic kidney disease. Take Quiz. ADPKD and diabetes onset risk after kidney ...
Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid ... Keywords: Biologic; anti-rheumatic drugs; bDMARDs; rheumatoid arthritis; targeted synthetic disease; treatment; tsDMARDs.. ... who do not achieve adequate clinical response with combined conventional synthetic disease-modifying anti-rheumatic drugs (cs- ...
The annual report for 2020 on the SA Rheumatic Heart Disease Control Program ... SA Rheumatic Heart Disease Control Program: Annual Report 2020. The annual report for 2020 on the SA Rheumatic Heart Disease ...

No FAQ available that match "rheumatic diseases"